GLP1R and type 2 diabetes mellitus: In this context, glucagon-like peptide-1 receptor (GLP-1R) agonists, such as liraglutide, originally developed for the treatment of type 2 diabetes, have demonstrated neuroprotective properties, including the ability to enhance insulin signaling in the brain, reduce amyloid deposition, and promote neuronal survival [6,7].